AU2002361028A1 - Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same - Google Patents

Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same

Info

Publication number
AU2002361028A1
AU2002361028A1 AU2002361028A AU2002361028A AU2002361028A1 AU 2002361028 A1 AU2002361028 A1 AU 2002361028A1 AU 2002361028 A AU2002361028 A AU 2002361028A AU 2002361028 A AU2002361028 A AU 2002361028A AU 2002361028 A1 AU2002361028 A1 AU 2002361028A1
Authority
AU
Australia
Prior art keywords
medicament
prevention
compounds
treatment
agent against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002361028A
Other versions
AU2002361028A8 (en
Inventor
Markus Bleich
Uwe Heinelt
Armin Hofmeister
Hans-Jochen Lang
Klaus Wirth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of AU2002361028A1 publication Critical patent/AU2002361028A1/en
Publication of AU2002361028A8 publication Critical patent/AU2002361028A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/10—Quaternary compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds of formula (I), where R1 to R10 have the meanings given in the claims are particularly suitable as anti-hypertensives, for the reduction or prevention of ischaemic induced injury, as medicament for operative intervention in the treatment of ischaemia of the nervous system, stroke, cerebral oedema, shock, disrupted respiration, treatment of snoring, as laxative, as agent against ectoparasites, for prevention of gallstone formation, as antiatherosclerotic, as agent against late diabetic complications, carcinogenic disease states, fibrotic diseases, endothelial dysfunctions, organ hypertrophias and hyperplasias. Said compounds are inhibitors of cellular sodium/proton antiporters, influence serum lipoproteins, and can be used for prophylaxis and regression of atherosclerotic changes.
AU2002361028A 2001-12-22 2002-12-09 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same Abandoned AU2002361028A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10163914A DE10163914A1 (en) 2001-12-22 2001-12-22 Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as medicament, and medicament containing them
DE10163914.7 2001-12-22
PCT/EP2002/013922 WO2003055880A2 (en) 2001-12-22 2002-12-09 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same

Publications (2)

Publication Number Publication Date
AU2002361028A1 true AU2002361028A1 (en) 2003-07-15
AU2002361028A8 AU2002361028A8 (en) 2003-07-15

Family

ID=7710835

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002361028A Abandoned AU2002361028A1 (en) 2001-12-22 2002-12-09 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same

Country Status (10)

Country Link
EP (1) EP1465870B1 (en)
JP (1) JP4495462B2 (en)
AT (1) ATE325100T1 (en)
AU (1) AU2002361028A1 (en)
CA (1) CA2471217A1 (en)
DE (2) DE10163914A1 (en)
MX (1) MXPA04005796A (en)
PE (1) PE20030721A1 (en)
TW (1) TW200304823A (en)
WO (1) WO2003055880A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312963A1 (en) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102004046492A1 (en) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102005001411A1 (en) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102005044815A1 (en) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Use of inhibitors of Na + / H + exchanger, subtype 5 (NHE5) for memory improvement
DE102005044817A1 (en) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102006012544A1 (en) * 2006-03-18 2007-09-27 Sanofi-Aventis Substituted 1-amino-4-phenyl-dihydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
MX2011007024A (en) * 2008-12-31 2011-09-27 Aedelyx Inc Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders.
BR112017000691B1 (en) 2014-07-25 2023-02-14 Taisho Pharmaceutical Co., Ltd PHENYLTETRAHYDROISOQUINOLINE REPLACED WITH HETEROARI-LA, ITS USE, DRUG, NHE3, SODIUM ABSORPTION AND PHOSPHORUS ABSORPTION INHIBITORS, INTESTINAL WATER SECRETION PROMOTER AND PROPHYLACTIC OR THERAPEUTIC DRUGS FOR CONSTIPATION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
DE4344550A1 (en) * 1993-12-24 1995-06-29 Hoechst Ag Substituted 1-oxo-1,2-dihydro-isoquinolinoyl and 1,1-dioxo-2H-1,2-benzothiazinoylguanidines, processes for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them
DE19951702A1 (en) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Use of 2-amino-3,4-dihydroquinazolines for the manufacture of a medicament for the treatment or prophylaxis of diseases caused by ischemic conditions
DE10019062A1 (en) * 2000-04-18 2001-10-25 Merck Patent Gmbh Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia

Also Published As

Publication number Publication date
JP2005524616A (en) 2005-08-18
DE10163914A1 (en) 2003-07-03
WO2003055880A2 (en) 2003-07-10
JP4495462B2 (en) 2010-07-07
CA2471217A1 (en) 2003-07-10
DE50206706D1 (en) 2006-06-08
EP1465870B1 (en) 2006-05-03
ATE325100T1 (en) 2006-06-15
TW200304823A (en) 2003-10-16
PE20030721A1 (en) 2003-10-03
AU2002361028A8 (en) 2003-07-15
WO2003055880A3 (en) 2003-11-06
EP1465870A2 (en) 2004-10-13
MXPA04005796A (en) 2004-09-10

Similar Documents

Publication Publication Date Title
TNSN04100A1 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof , the use thereof as medicaments, in addition to a medicament containing same
NL300933I2 (en) Letermovir
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
NO20055680L (en) Hexahydropyridoisoquinolines as DPP-IV inhibitors
WO2007075833A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
BRPI0508392A (en) Materials and Methods for Treating Coagulation Disorders
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
BR0209957A (en) Compound, process for preparing a compound, pharmaceutical composition comprising a compound, use of such compound and process for the treatment and prophylaxis of arthritis, diabetes, eating disorders and obesity
CY1109191T1 (en) A NEW USE OF DIFFERIPRON
CA2534428A1 (en) Melanin concentrating hormone receptor antagonists
WO2002000218A3 (en) Methods of treating neutrophil-related diseases with topical anesthetics
AU2002361028A1 (en) Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
IL156467A0 (en) Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same
WO2010151778A3 (en) Topical compositions and methods for wound care
MX2010003071A (en) Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain.
NO20022801L (en) Substituted norbornylamino derivatives, processes for their preparation, their use as a medicament or diagnostic as well as drugs containing these
BRPI0511323A (en) Substituted tetrahydroisoquinolines used in the form of mmp inhibitors, method for their production and use as dragees
WO2001070737A3 (en) Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
WO2002098843A3 (en) Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
WO2002000611A3 (en) Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
TW200512209A (en) Treating and/or preventing agent for pulmonary diseases
BR0307039A (en) Compounds, in particular urea derivatives or esters of haloacetamidobenzoic acid and their use in the treatment of parasitic diseases.
BR0309403A (en) Use of hydroxypyridone derivatives in wound healing

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase